长春高新回应儿童小阴茎专用药获批：上市至少要三年

Core Viewpoint - Changchun High-tech's stock price declined over 4% following the announcement of the approval for a pediatric medication, with the company indicating that the drug will take at least three years to reach the market [1] Group 1: Company Developments - Changchun High-tech's subsidiary, GenSci, received approval for clinical trials of GenSci141 ointment, aimed at treating conditions leading to pediatric micropenis [1] - The company stated that the timeline from clinical approval to market launch is typically a minimum of three years, subject to uncertainties in each trial phase [1] Group 2: Market Reaction - Following the announcement, Changchun High-tech's stock opened lower, trading at 95.88 yuan per share at the time of reporting [1] - A representative from the company's securities department commented that the stock price fluctuations do not have any special reasons behind them [1]